MCRB vs. PALI

Last updated Apr 2, 2026

Compare and contrast key facts about Seres Therapeutics, Inc. (MCRB) and Palisade Bio, Inc. (PALI).

Performance

MCRB vs. PALI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Seres Therapeutics, Inc. (MCRB) and Palisade Bio, Inc. (PALI). The values are adjusted to include any dividend payments, if applicable.

MCRB vs. PALI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
MCRB Seres Therapeutics, Inc.	-40.46%	-10.47%	-40.64%	-75.00%	-32.77%	-66.00%	610.14%	-23.67%	-55.42%	2.42%
PALI Palisade Bio, Inc.	-20.00%	42.42%	-81.36%	-88.65%	-92.00%	-75.38%	-11.11%	-84.19%	-81.80%	-51.61%

Fundamentals

Market Cap MCRB : $78.59M PALI : $104.66M
EPS MCRB : $0.65 PALI : -$0.74
PB Ratio MCRB : 1.78 PALI : 0.81
Total Revenue (TTM) MCRB : $789.00K PALI : $0.00
Gross Profit (TTM) MCRB : -$22.17M PALI : $0.00
EBITDA (TTM) MCRB : $6.98M PALI : -$18.06M

Returns By Period

In the year-to-date period, MCRB achieves a -40.46% return, which is significantly lower than PALI's -20.00% return. Over the past 10 years, MCRB has outperformed PALI with an annualized return of -33.84%, while PALI has yielded a comparatively lower -72.84% annualized return.

MCRB

• 1D: -0.11%
• 1M: -1.12%
• YTD: -40.46%
• 6M: -56.78%
• 1Y: -34.49%
• 3Y*: -57.25%
• 5Y*: -53.53%
• 10Y*: -33.84%

PALI

• 1D: 7.43%
• 1M: 3.87%
• YTD: -20.00%
• 6M: 43.51%
• 1Y: 180.68%
• 3Y*: -67.10%
• 5Y*: -81.01%
• 10Y*: -72.84%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

MCRB vs. PALI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MCRB

MCRB Risk / Return Rank: 30
MCRB Sharpe Ratio Rank: 26
MCRB Sortino Ratio Rank: 36
MCRB Omega Ratio Rank: 37
MCRB Calmar Ratio Rank: 24
MCRB Martin Ratio Rank: 24

PALI

PALI Risk / Return Rank: 84
PALI Sharpe Ratio Rank: 83
PALI Sortino Ratio Rank: 89
PALI Omega Ratio Rank: 81
PALI Calmar Ratio Rank: 85
PALI Martin Ratio Rank: 83

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MCRB vs. PALI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Seres Therapeutics, Inc. (MCRB) and Palisade Bio, Inc. (PALI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MCRB	PALI	Difference
Sharpe ratio Return per unit of total volatility	-0.30	1.48	-1.79
Sortino ratio Return per unit of downside risk	0.33	2.76	-2.43
Omega ratio Gain probability vs. loss probability	1.05	1.30	-0.26
Calmar ratio Return relative to maximum drawdown	-0.51	3.12	-3.63
Martin ratio Return relative to average drawdown	-0.92	7.20	-8.12
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MCRB vs. PALI - Sharpe Ratio Comparison

The current MCRB Sharpe Ratio is -0.30, which is lower than the PALI Sharpe Ratio of 1.48. The chart below compares the historical Sharpe Ratios of MCRB and PALI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	MCRB	PALI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.30	1.48	-1.79
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.51	-0.55	+0.04
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.22	-0.52	+0.30
Sharpe Ratio (All Time) Calculated using the full available price history	-0.24	-0.45	+0.21

Correlation

The correlation between MCRB and PALI is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

MCRB vs. PALI - Dividend Comparison

Neither MCRB nor PALI has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

MCRB vs. PALI - Drawdown Comparison

The maximum MCRB drawdown since its inception was -99.34%, roughly equal to the maximum PALI drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for MCRB and PALI.

Drawdown Indicators

	MCRB	PALI	Difference
Max Drawdown Largest peak-to-trough decline	-99.34%	-100.00%	+0.66%
Max Drawdown (1Y) Largest decline over 1 year	-71.50%	-56.53%	-14.97%
Max Drawdown (5Y) Largest decline over 5 years	-98.61%	-99.99%	+1.38%
Max Drawdown (10Y) Largest decline over 10 years	-99.10%	-100.00%	+0.90%
Current Drawdown Current decline from peak	-99.14%	-100.00%	+0.86%
Average Drawdown Average peak-to-trough decline	-81.11%	-76.07%	-5.04%
Ulcer Index Depth and duration of drawdowns from previous peaks	39.88%	24.46%	+15.42%

Volatility

MCRB vs. PALI - Volatility Comparison

The current volatility for Seres Therapeutics, Inc. (MCRB) is 19.52%, while Palisade Bio, Inc. (PALI) has a volatility of 22.29%. This indicates that MCRB experiences smaller price fluctuations and is considered to be less risky than PALI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MCRB	PALI	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.52%	22.29%	-2.77%
Volatility (6M) Calculated over the trailing 6-month period	83.10%	90.49%	-7.39%
Volatility (1Y) Calculated over the trailing 1-year period	114.83%	122.50%	-7.67%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	104.85%	146.34%	-41.49%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	154.19%	141.03%	+13.16%

Financials